6,419 Illumina, Inc. $ILMN Shares Sold by D.A. Davidson & CO.

D.A. Davidson & CO. cut its stake in Illumina, Inc. (NASDAQ:ILMN) by 27.9% in the third quarter, Holdings Channel.com reports. The firm owned 16,601 shares of the life sciences company’s stock after selling 6,419 shares during the quarter. D.A. Davidson & CO.’s holdings in Illumina were worth $4,543,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ILMN. Fiduciary Financial Advisors acquired a new stake in shares of Illumina in the second quarter valued at approximately $26,000. MCF Advisors LLC raised its stake in shares of Illumina by 172.4% during the 2nd quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 100 shares in the last quarter. Keating Financial Advisory Services Inc. bought a new stake in shares of Illumina during the 2nd quarter worth approximately $32,000. Rakuten Securities Inc. acquired a new stake in shares of Illumina in the 2nd quarter valued at approximately $33,000. Finally, WealthCollab LLC increased its holdings in Illumina by 51.5% during the first quarter. WealthCollab LLC now owns 303 shares of the life sciences company’s stock worth $37,000 after buying an additional 103 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Key Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Illumina reported third-quarter adjusted EPS of $1.44, above the $1.36 consensus estimate, while revenue increased 4.2% year over year to approximately $1.13 billion. Illumina Reports Financial Results for Third Quarter
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 outlook, with revenue guidance of roughly $4.65 billion at the midpoint, supported by clinical sequencing demand and continued adoption of the NovaSeq X platform. ILMN Q3 Earnings Call Highlights
• Positive Sentiment: Long-term industry demand remains favorable. Recent market reports point to strong growth in clinical genomics, sequencing-as-a-service, population screening, and AI-enabled genomic analysis—markets in which Illumina is a major participant. These reports are industry forecasts rather than new company contracts or financial commitments.
• Neutral Sentiment: Analyst sentiment became more cautious. JPMorgan reduced its price target from $320 to $300, while Robert W. Baird maintained a Hold rating. The target cut suggests less near-term upside following Illumina’s substantial prior rally. JPMorgan Adjusts Price Target
• Negative Sentiment: Revenue performance disappointed investors. Although earnings surpassed estimates, quarterly revenue was below consensus in several reports, highlighting softer demand than expected and limiting the impact of the profit beat.
• Negative Sentiment: China exposure, tariffs, and business mix remain concerns. Investors are worried about China-related revenue challenges, tariff uncertainty, research-market weakness, and pricing pressure. A broader pullback in AI-linked technology stocks also hurt sentiment toward Illumina. Illumina Shares Tumble on China Woes

Insider Activity at Illumina

In related news, Director Keith Meister sold 457,858 shares of the company’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the sale, the director directly owned 2,372,694 shares in the company, valued at $474,776,069.40. This represents a 16.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders sold 2,061,235 shares of company stock worth $436,356,102. 2.90% of the stock is currently owned by insiders.

Illumina Stock Performance

NASDAQ:ILMN opened at $235.99 on Friday. The company has a market cap of $35.63 billion, a price-to-earnings ratio of 40.62, a PEG ratio of 3.34 and a beta of 1.41. Illumina, Inc. has a fifty-two week low of $106.12 and a fifty-two week high of $309.35. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The stock has a fifty day moving average price of $249.30 and a 200-day moving average price of $176.18.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.36 by $0.26. The business had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. Illumina had a net margin of 19.72% and a return on equity of 29.41%. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter last year, the business posted $1.34 EPS. As a group, equities analysts anticipate that Illumina, Inc. will post 5.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Citigroup lifted their price objective on shares of Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research report on Monday, August 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Illumina in a report on Monday, August 31st. Leerink Partners upped their target price on shares of Illumina from $220.00 to $300.00 and gave the company an “outperform” rating in a report on Tuesday, September 29th. TD Cowen raised their target price on shares of Illumina from $210.00 to $270.00 and gave the company a “hold” rating in a research note on Tuesday, October 13th. Finally, Guggenheim lifted their price target on Illumina from $226.00 to $305.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $238.53.

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.